Novartis in the US – The Big Picture
Novartis is a world leader in the research and development of products that protect and improve
health and well-being. Our global mission is to discover, develop and successfully market inno-
vative products to ease suffering and enhance the quality of life. Novartis is the only major
pharmaceutical company with leadership positions in both patented prescription medicines and
Over the years, Novartis has been recognized for its admirable reputation, commitment to ethics,
its status as a respected pillar of the industry and for being an outstanding workplace for its
employees. In recent years we’ve been named among the “Most Admired” (FORTUNE), “Most
Respected” (Barron’s) and “Most Ethical” (Ethisphere) companies in the world.
Our US organization is made up of companies divided into four divisions with active operations
spanning 20 cities and responsible for generating nearly a third of our global revenue. Together,
these units function side-by-side under the umbrella of Novartis Corporation, a US holding com-
pany responsible for Group level matters such as finance, investor relations and communications.
Novartis Group Total 2008
Global Sales: $41,459 million
Novartis Group 2008 Global Sales
Novartis Group Total 2008
US Sales: $12,861 million
Novartis Group 2008 US Sales
*The Novartis Consumer Health Division is
made up of the OTC, Animal Health and
CIBA VISION Business Units
Total Novartis Group US employees:
Our US employees by division:
*Includes NIBR and GNF associates
WHAT WE DO
• We are ranked as a leader
for having one of the best
combinations of growing
brands and a promising
• Our clinical pipeline holds
a broad stream of 152
projects including both
new molecular entities and
additional indications or
formulations for marketed
HOW WE WORK
Our US divisions/business
• Novartis Pharmaceuticals
• Novartis Oncology
• Novartis Vaccines and
• Sandoz (generics)
• Novartis Institutes for
BioMedical Research (NIBR)
• OTC (over-the-counter
• Novartis Animal Health
• CIBA VISION
WHO WE ARE
• Novartis was created in 1996
by the merger of Swiss
companies Ciba-Geigy and
Sandoz. With global head-
quarters in Basel, Switzerland,
the Novartis Group companies
employ nearly 98,000 people
in more than 140 countries.
• Our largest division was recently
named to DiversityInc’s Top
50 Companies for diversity
and Working Mother’s 100
Best Companies for 10 years
For the Novartis Group, the US is a major center of
research and development (R&D), manufacturing, sales
and marketing. More than 20% of the Novartis Group’s
employees are based here.
Novartis invests in these four strategic growth platforms
Helping patients get access
to needed medicines
At Novartis, not only are we
committed to making medicines,
we are also dedicated to improv-
ing access to them. We recognize
that many patients today face
obstacles that keep them from
getting the medicines they need,
so we work to lend a helping hand.
• Last year, our patient assistance
programs reached 74 million
patients worldwide, with contri-
butions totaling $1.26 billion.
• In 2009, Novartis delivered its
250 millionth malaria treatment.
With an estimated 630,000
lives saved, Novartis nonprofit
Malaria Initiative is the largest
for the developing world.
• Since 2002, Novartis has
donated more than one billion
dollars’ worth of one of our
breakthrough cancer treatments
to patients and governments.
• In the US, we are proud to offer
Patient Assistance Now, an easy
to use, comprehensive resource
allowing patients to access
programs that may help pay for
their Novartis medicines and
provide information they may
need to take care of their health.
The PHARMACEUTICALS DIVISION of Novartis is recognized worldwide for the innovative
medicines we provide to patients, physicians and healthcare organizations. Our current product
portfolio in therapeutic areas such as Cardiology, Oncology, Respiratory, and Neuroscience
contains more than 50 key marketed prescription drugs, many of which are leaders in their
In our Oncology Business Unit, our employees share a common mission to discover and develop
innovative medicines to fight cancer. Headquartered in Florham Park, New Jersey, we are
passionate about providing a broad range of new remedies and practical solutions that
change the way patients live with cancer.
At NOVARTIS VACCINES AND DIAGNOSTICS, caring begins with prevention. Every 25 sec-
onds, someone in the world is given a Novartis vaccine. Our division’s purpose is to look after
the well-being of people through our innovative vaccines and diagnostics tools designed to
prevent the spread of life-threatening diseases and protect vulnerable populations. Novartis
Vaccines is focused on creating innovative products to prevent influenza, meningitis and more
than 20 vaccine-preventable viral and bacterial diseases. Novartis Diagnostics is dedicated to
preventing the spread of infectious diseases through sophisticated blood-testing equipment
that screens blood donations for infection.
In Cambridge, MA, NV&D researchers at the Center of Excellence in Virology are working on a
vaccine for H1N1 influenza.
SANDOZ is the generic pharmaceuticals division of Novartis and a global leader in the rapidly
growing generics industry. Sandoz develops, produces and markets medicines no longer pro-
tected by patents, along with pharmaceutical and biotechnological active substances, and sells
them to wholesalers, pharmacies, hospitals and other healthcare outlets. Having cultivated
the ability to develop and produce a wide range of difficult-to-make medicines, from complex
delivery systems for standard generics to modern biopharmaceutical medicines (biosimilars),
Sandoz stands out for making far more than just traditional off-patent medicines.
Through our global network, Sandoz generic medicines are available to 90% of people worldwide.
Our CONSUMER HEALTH DIVISION creates, develops and manufactures a wide range of
products designed to restore, maintain or improve the health and well-being of consumers. A
number of our products have become household brands in America, including Keri®
, Air Optix®
• OTC (i.e., “over-the-counter” products) is a world leader in the research, development, pro-
duction and marketing of self-medication products that do not require a prescription.
We have the fastest growing OTC company among the top five global players in the industry.
• Novartis Animal Health focuses on the well-being of companion animals and the health
and productivity of farm animals.
Novartis produces the market-leading drug for heart disease in dogs and kidney failure in cats.
• CIBA VISION is a global leader in the research, development and manufacturing of contact
lenses and lens care products.
CIBA VISION offers the widest variety of colors, modalities and color contact lens styles of any
contact lens manufacturer.
The path from scientific breakthrough to suc-
cessful pharmaceutical brand depends on
mobilizing the best global resources, expertise
At Novartis, we often achieve success
through close collaboration with companies
and institutions who share a common vision
and complementary strengths. A key Novartis
priority is to build winning collaborations in
the research of new medicines and vaccines.
For instance, through the NIBR Strategic
Alliances Group, NIBR has established produc-
tive alliances with over 300 collaborators, both
academic and industrial. Current US collabo-
• Alnylam Pharmaceuticals
• CombinatoRx, Inc.
• Dana Farber Cancer Institute
• Gen-Probe, Inc.
• Human Genome Sciences, Inc.
• Idenix Pharmaceuticals, Inc.
• Idera Pharmaceuticals, Inc.
• Massachusetts General Hospital (MGH)
• Massachusetts Institute of Technology (MIT)
• The Institute for OneWorld Health
• The Scripps Research Institute
Research & Development in the US begins and ends with
Our strategy is to focus on discovery projects at the intersection of powerful scientific
mechanisms and greatest medical need
R&D collaborations across the US
Novartis Institutes of
BioMedical Research (NIBR)
Three of six NIBR sites in the
world are located in the US, focus-
ing on diverse disease areas
• Infectious diseases
East Hanover, NJ
Genomics Institute of
the Novartis Research
La Jolla, CA
One of our four
the globe is in California.
Researchers at GNF develop and
apply advanced technologies to
identify new biological processes
and understand the underlying
mechanisms of disease.
Biologics are at the cutting-edge of drug discovery—they
already represent a quarter of our R&D pipeline! The
Novartis Biologics unit, launched in 2007, is dedicated
to the ultimate goal of delivering customized, targeted
biologic therapies that can improve the lives of patients.
Scientists at Novartis are accelerating develop-
ment of innovative medicines with cutting-edge
tools and close cooperation among multi-dis-
ciplinary teams to translate fundamental
science into treatments. To do this, they are
using the latest technologies and approaches
to drug discovery—integrating clinical insights
with mechanistic understanding of diseases to
get an early readout on a drug’s safety and
effectiveness. This enables us to find and advance
the most promising drug candidates.
Novartis completes proof-of-concept studies
to confirm a medicine’s mechanism of action
and explores multiple disease indications before
full development begins. By also modeling the
activity of medicines and vaccines, we are able
to make better decisions and bring more and
better new medicines to market in a shorter time.
Collaborations with biotech and academia help
further strengthen the clinical pipeline.
NIBR associates in Cambridge, MA,
are playing a role in developing the
next generation of research talent
through the Netpals program, which
pairs Novartis scientists with local
public school students for one-on-one
mentoring and correspondence.